Urihk Pharmaceuticals (“URIHK” or “Urihk”), a subsidiary of UREKA Hong Kong Ltd., has built a strong foundation in India by launching and distributing innovative drugs in the critical care segment. With a network spanning more than 55 countries, we are known for proliferating reliable and diverse therapies that make a real difference in people’s lives. Urihk began as a partnership between three highly experienced companies: Jiangsu Aidea Pharmaceutical (“Aidea”), Joint Force Pharmaceutical Limited (“JFPL”), and Shenzhen Mellow Hope Pharm Limited (“Mellow Hope”). The Urihk Partnership continues to grow and evolve, leveraging learnings and expertise to bring the best the world has on offer to India. Urihk’s mission is to help save lives through the development and distribution of groundbreaking products. We aim to provide innovative products at optimal pricing, to suit a wide range of customers in the critical care segment. Our top priority is always the requirements of medical professionals and their patients; at Urihk, we strive to emphasize the ‘U’ before the ‘I’. Urihk is entirely invested in becoming a leading name in the critical care/ICU segment, in India and beyond. We provide a unique product range for our extensive customers, and are constantly looking for better ways to connect with new partners globally. Count on us to fulfill the unmet needs of Indian patients. Count on us to help you build a better India.